Electromed, Inc. reported significant financial growth in its latest quarterly filing, with net revenues reaching $18.9 million for the three months ended December 31, 2025, a 16.3% increase from $16.3 million in the same period last year. For the six months ending December 31, 2025, revenues totaled $35.8 million, up 15.7% from $30.9 million in the prior year. The company’s net income also saw a substantial rise, increasing by 40.3% to $2.8 million for the quarter and 42.3% to $4.9 million for the half-year, driven by higher sales and improved gross profit margins.
The company experienced notable changes in its revenue streams, particularly in the homecare segment, which generated $17.3 million in the latest quarter, an 18.4% increase year-over-year. This growth was attributed to an increase in the number of direct sales representatives and higher revenue per representative. Conversely, hospital revenue decreased by 9.4% to $655,000 for the quarter, reflecting fewer capital equipment orders, although it increased by 20.5% for the six-month period. Homecare distributor revenue also rose by 12.1% for the quarter and 24.4% for the half-year, indicating strong demand from distribution partners.
Electromed's operational metrics showed a steady increase in its workforce, with an average of 58 homecare field sales representatives contributing to the revenue growth. The company’s total assets increased to $54.9 million as of December 31, 2025, compared to $53.8 million at the end of June 2025. Shareholders' equity also rose to $45.4 million, reflecting a solid financial position. The company has maintained a focus on enhancing its product offerings, including the SmartVest Clearway® Airway Clearance System, which received FDA clearance in November 2022.
In terms of strategic developments, Electromed entered into a credit agreement with BMO Bank N.A. in December 2025, establishing a $10 million revolving line of credit to support its operational needs. The company has also initiated a stock repurchase program, authorizing the repurchase of up to $10 million of its common stock, with $3.8 million already utilized for share buybacks. Looking ahead, Electromed anticipates continued growth driven by its expanding sales force and product adoption, while also navigating potential challenges such as market competition and regulatory changes. The company expects its current liquidity position, bolstered by cash reserves and available credit, to adequately support its operational and capital needs for the upcoming year.
About Electromed, Inc.
Electromed, Inc. develops, manufactures, and markets the SmartVest airway clearance system, primarily serving patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions. Its products use high-frequency chest wall oscillation (HFCWO) to improve respiratory function, reduce infections, and lower healthcare costs. The company employs a direct-to-patient and provider sales model, focusing on clinical evidence, reimbursement support, and product innovation in the U.S. and select international markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.